Forsta AP Fonden Has $6.35 Million Stock Position in Natera, Inc. $NTRA

Key Points

• Forsta AP Fonden cut its Natera stake by 37% in the fourth quarter, selling 16,300 shares and leaving it with 27,700 shares worth about $6.35 million.
• Institutional ownership remains very high, with 99.90% of Natera shares held by institutions. Several funds increased or initiated positions, including JPMorgan Chase, Robinhood Asset Management, and others.
• Analyst sentiment is broadly positive: Natera has a Moderate Buy consensus rating with a $256.60 average target price, though there are some mixed views, including a recent sell rating from Weiss Ratings.

Forsta AP Fonden reduced its holdings in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 37.0% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 27,700 shares of the medical research company's stock after selling 16,300 shares during the quarter. Forsta AP Fonden's holdings in Natera were worth $6,346,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. Robinhood Asset Management LLC bought a new position in shares of Natera in the fourth quarter worth about $12,981,000. JPMorgan Chase & Co. lifted its holdings in shares of Natera by 9.4% in the third quarter. JPMorgan Chase & Co. now owns 11,628,914 shares of the medical research company's stock worth $1,871,914,000 after acquiring an additional 1,003,129 shares during the last quarter. Krilogy Financial LLC bought a new position in shares of Natera in the third quarter worth about $1,323,000. Zweig DiMenna Associates LLC lifted its holdings in shares of Natera by 6.8% in the third quarter. Zweig DiMenna Associates LLC now owns 132,500 shares of the medical research company's stock worth $21,329,000 after acquiring an additional 8,400 shares during the last quarter. Finally, Systrade AG bought a new position in shares of Natera in the fourth quarter worth about $11,454,000. 99.90% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

NTRA has been the subject of several research reports. JPMorgan Chase & Co. increased their target price on Natera from $260.00 to $265.00 and gave the company an "overweight" rating in a research report on Friday, May 8th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Natera in a research report on Tuesday, April 21st. Robert W. Baird set a $265.00 target price on Natera in a research report on Friday, May 8th. William Blair initiated coverage on Natera in a research report on Tuesday, April 14th. They issued an "outperform" rating for the company. Finally, Evercore reiterated an "outperform" rating and issued a $270.00 target price on shares of Natera in a research report on Friday, May 8th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Natera has a consensus rating of "Moderate Buy" and a consensus target price of $256.60.

Natera Price Performance

Shares of NTRA opened at $218.81 on Tuesday. Natera, Inc. has a 1 year low of $131.81 and a 1 year high of $256.36. The company has a market capitalization of $31.34 billion, a price-to-earnings ratio of -134.24 and a beta of 1.56. The business has a 50-day moving average of $202.69 and a 200-day moving average of $215.84.

Insider Buying and Selling

In other Natera news, insider Solomon Moshkevich sold 3,405 shares of Natera stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $203.69, for a total value of $693,564.45. Following the completion of the sale, the insider directly owned 142,295 shares in the company, valued at approximately $28,984,068.55. The trade was a 2.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Steven Leonard Chapman sold 5,838 shares of Natera stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $204.14, for a total value of $1,191,769.32. Following the completion of the sale, the chief executive officer owned 150,769 shares of the company's stock, valued at approximately $30,777,983.66. The trade was a 3.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 34,406 shares of company stock valued at $6,984,955 over the last three months. 5.05% of the stock is owned by insiders.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.